Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralisation and commercial assays
Abstract We conducted a prospective study in healthcare workers (n=296) of the University Hospital of Lyon, France. Serum samples (n=296) collected six months after disease onset were tested using three commercial assays: the Wantai Ab assay detecting total antibodies against the receptor binding domain (RBD) of the S protein, the bioMerieux Vidas assay detecting IgG to the RBD and the Abbott Architect assay detecting IgG to the N protein. The neutralising antibody (NAb) titre was also determined for all samples with a virus neutralisation assay (VNA) using live virus. The positivity rate was 100% with the Wantai assay, 84.8% with the bioMerieux assay and 55.4% with the Abbott assay. Only 51% of HCWs were positive for the presence of NAb. Less than 10 % of HCWs had a NAb titre greater than 80. At a neutralising titre of 80, the area under the curves [IC 95%] was 0.71 [0.62-0.81], 0.75 [0.65-0.85] and 0.95 [0.92-0.97] for Wantai, Abbott and Vidas respectively. The data presented herein suggest that commercial assays detecting antibodies against the N protein must not be used in long-term seroprevalence surveys while the Wantai assay could be useful for this purpose. VNA should remain the gold standard to assess the protective antibody response, but some commercial assays could be used as first-line screening of long-term presence of NAb..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 30. Dez. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bal, Antonin [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.12.08.20245811 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019524919 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019524919 | ||
| 003 | DE-627 | ||
| 005 | 20230429092250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201211s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.12.08.20245811 |2 doi | |
| 035 | |a (DE-627)XBI019524919 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.12.08.20245811 | ||
| 035 | |a (biorXiv)10.1101/2020.12.08.20245811 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Bal, Antonin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralisation and commercial assays |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract We conducted a prospective study in healthcare workers (n=296) of the University Hospital of Lyon, France. Serum samples (n=296) collected six months after disease onset were tested using three commercial assays: the Wantai Ab assay detecting total antibodies against the receptor binding domain (RBD) of the S protein, the bioMerieux Vidas assay detecting IgG to the RBD and the Abbott Architect assay detecting IgG to the N protein. The neutralising antibody (NAb) titre was also determined for all samples with a virus neutralisation assay (VNA) using live virus. The positivity rate was 100% with the Wantai assay, 84.8% with the bioMerieux assay and 55.4% with the Abbott assay. Only 51% of HCWs were positive for the presence of NAb. Less than 10 % of HCWs had a NAb titre greater than 80. At a neutralising titre of 80, the area under the curves [IC 95%] was 0.71 [0.62-0.81], 0.75 [0.65-0.85] and 0.95 [0.92-0.97] for Wantai, Abbott and Vidas respectively. The data presented herein suggest that commercial assays detecting antibodies against the N protein must not be used in long-term seroprevalence surveys while the Wantai assay could be useful for this purpose. VNA should remain the gold standard to assess the protective antibody response, but some commercial assays could be used as first-line screening of long-term presence of NAb. | ||
| 700 | 1 | |a Trabaud, Mary-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Fassier, Jean-Baptiste |e verfasserin |4 aut | |
| 700 | 1 | |a Rabilloud, Muriel |e verfasserin |4 aut | |
| 700 | 1 | |a Saker, Kahina |e verfasserin |4 aut | |
| 700 | 1 | |a Langlois-Jacques, Carole |e verfasserin |4 aut | |
| 700 | 1 | |a Guibert, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a d’Aubarede, Constance |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Adèle |e verfasserin |4 aut | |
| 700 | 1 | |a Alfaiate, Dulce |e verfasserin |4 aut | |
| 700 | 1 | |a Massardier-Pilonchery, Amélie |e verfasserin |4 aut | |
| 700 | 1 | |a Pitiot, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Morfin-Sherpa, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Lina, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Pozzetto, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Trouillet-Assant, Sophie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 30. Dez. |
| 773 | 1 | 8 | |g year:2020 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.08.20245811 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 30 |c 12 | ||
| 953 | |2 045F |a 570 | ||